Pfizer is making headlines again following the latest reports. Check out the news about the pharmaceutical giant below.
CNBC just revealed that Pfizer and BioNTech on Friday said they were delaying their request for the Food and Drug Administration to authorize their Covid-19 vaccine for children under five until early April.
It seems that they are waiting on more data on the effectiveness of a third dose.
“Given that the study is advancing at a rapid pace, the companies will wait for the three-dose data as Pfizer and BioNTech continue to believe it may provide a higher level of protection in this age group.”
This is what Pfizer said in a statement.
Pfizer said it needed more data “because rates of infection and illness remain high in children of this age” due to the omicron variant.
The FDA said it’s postponing a meeting Tuesday that was scheduled to look at the kids’ data.
“The delay comes as a disappointment to parents who are anxiously awaiting the chance to vaccinate their children against Covid. Children under 5 years old are the last age group left in the U.S. that isn’t eligible for vaccination.”
Pfizer in the news
It’s been just revealed that an extremely important pharmaceutical executive is saying that pandemic-related restrictions could be relaxed.
This is happening as cases decline in some areas following a surge of the milder Omicron variant.
Dr. Scott Gottlieb is a former director of the Food and Drug Administration (FDA) and current board member at Pfizer.
“I think certainly on the East Coast, where you see cases declining dramatically, we need to be willing to lean in and do that very soon I think as conditions improve we have to be willing to relax some of these measures with the same speed that we put them in place.”
This is what he said on CNBC.
